• CHMP medtog i sine overvejelser, at benefit/ risk- forholdet for Hexavac til primærvaccination og booster- vaccination af børn mod difteri, stivkrampe, kighoste, hepatitis B, forårsaget af alle kendte virussubtyper, børnelammelse og invasive infektioner, forårsaget af Haemophilus influenzae type b, ikke var gunstigt.
• The CHMP considered that the benefit/ risk balance of Hexavac for primary and booster vaccination of children against diphtheria, tetanus, pertussis, Hepatitis B caused by all known subtypes of viruses, poliomyelitis and invasive infections caused by Haemophilus influenzae type b, was not favourable.